Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in ...
elpasoinc.com
news
2022-05-31 12:02:55

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's progress and business plans; plans, timelines, and expectations related to BIIB122 (DNL151), including with respect to the ongoing Phase 2b LUMA study and the timing and expectations of the planned Phase 3 LIGHTHOUSE study; the potential of BIIB122 (DNL151) to be a treatment for Parkinson's disease and a first-in-class oral therapy; the potential for LRRK2 inhibition to slow the progression of Parkinson's disease in certain patients; the potential benefits and likelihood of success of, activity under, and expectations related to Denali's collaboration with Biogen; and statements made by Denali's Chief Medical Officer and Biogen's Senior Vice President, Global Safety & Regulatory Sciences.
